Latest News - Bristol-Myers Squibb
Top Corporates Hub
Bristol-Myers Squibb
Will Camzyos Strengthen BMY's Cardiovascular Portfolio?
27.08.2025 14:05
Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.
How Investors May Respond To ACADIA Pharmaceuticals (ACAD) Hiring an Industry Veteran for Growth Strategy
27.08.2025 10:19
On August 25, 2025, Acadia Pharmaceuticals announced the appointment of Konstantina (“Tina”) Katcheves as Senior Vice President, Chief Business and Strategy Officer, bringing her extensive leadership experience from Teva Pharmaceuticals and Bristol Myers Squibb. Katcheves’s proven record in advancing major pharmaceutical transactions and expanding innovative pipelines highlights Acadia’s intent to strengthen its growth and business development capabilities. We'll explore how Katcheves’s...
Branded Pharmaceuticals Stocks Q2 Recap: Benchmarking Bristol-Myers Squibb (NYSE:BMY)
27.08.2025 03:32
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Bristol-Myers Squibb (NYSE:BMY) and its peers.
[Latest] Global Targeted Drug Delivery Market Size/Share Worth USD 39.6 Billion by 2034 at a 15.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
25.08.2025 11:30
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Targeted Drug Delivery Market size & share revenue was valued at approximately USD 9.8 Billion in 2024 and is expected to reach USD 11.4 Billion in 2025 and is expected to reach around USD 39.6 Billion by 2034, at a CAGR of 15.5% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Bristol-Myers Squibb, Pfiz
Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
25.08.2025 10:59
PRINCETON, N.J., August 25, 2025--Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
Should You Revisit Bristol-Myers Squibb Amid Uncertainty Over Pharma Tariffs in 2025?
25.08.2025 10:24
If you are eyeing Bristol-Myers Squibb and wondering whether it deserves a spot in your portfolio, you are not alone. At a recent close of $47.92, it is a stock that’s been getting more attention, but for reasons on both sides. Over the past year, its return has been a modest 4.0%, which may not be especially exciting. Looking at a longer period, the three-year and five-year returns come in at -18.5% and -7.0% respectively. Bristol-Myers Squibb has not been delivering strong growth recently,...
Bristol Myers: presentations scheduled at ESC Congress
25.08.2025 08:09
Bristol Myers Squibb says that new clinical and real-world data from its cardiovascular portfolio will be presented at the European Society of Cardiology Congress, which will be held August...
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
19.08.2025 13:00
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution
13.08.2025 05:25
Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions Reporting segment formerly known as Shared R&D renamed to Discovery & Preclinical Development ("D&PD") to better reflect ...
Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions
13.08.2025 04:25
Bristol-Myers Squibb’s second quarter saw flat overall sales, but the company surpassed Wall Street expectations for both revenue and non-GAAP profit, with operating margin improving year on year. Despite these beats, the market responded negatively, reflecting concerns raised by management about continued macro and competitive pressures. CEO Chris Boerner pointed to strong demand across the company’s growth portfolio, especially in oncology and hematology, while also acknowledging regulatory wi
BMY Q2 Deep Dive: Pipeline Progress, Guidance Revision, and Strategic Partnerships Shape Outlook
13.08.2025 04:00
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company’s full-year revenue guidance of $47 billion at the midpoint came in 1.6% above analysts’ estimates. Its non-GAAP profit of $1.46 per share was 32.6% above analysts’ consensus estimates.
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
12.08.2025 11:00
$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates Newly appointed board and management team includes Dr. Adam Craig as Executive Chairman, John Volpone as President and David Kirske as Chief Financial Officer BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it has entered into a securities purchase a
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda
12.08.2025 10:59
The Global Multiple Myeloma Market is projected to grow from USD 21.78 billion in 2024 to USD 40.41 billion by 2033, at a CAGR of 7.11%. Growth drivers include rising multiple myeloma cases, advances in targeted therapies like monoclonal antibodies, and the increasing adoption of immunotherapies. Enhanced diagnostics and greater healthcare accessibility are boosting market expansion. Key regions such as the U.S., Europe, and Asia-Pacific, are witnessing heightened therapy adoption. Challenges in
Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise
12.08.2025 06:57
Biotechs are coming to the island as tariffs threaten overseas drug exports, and finding Puerto Rico is more than just a leading manufacturing hub.
The Strong Earnings Posted By Bristol-Myers Squibb (NYSE:BMY) Are A Good Indication Of The Strength Of The Business
07.08.2025 10:57
Even though Bristol-Myers Squibb Company's ( NYSE:BMY ) recent earnings release was robust, the market didn't seem to...
Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth
05.08.2025 15:47
PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost cuts.
Why Investors Should Expect The July CPI To Tick Higher
05.08.2025 13:15
Tariff risks remain high for July CPI. A higher CPI print increases the likelihood of a Fed rate cut. Check out the expected implications of July CPI report.
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
05.08.2025 13:10
EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
05.08.2025 13:00
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO
05.08.2025 12:17
Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to-consumer options.